The Bio-Rad iQ-Check Aspergillus Real-Time PCR Detection Kit Receives AOAC International Approval
HERCULES, Calif. — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced that AOAC INTERNATIONAL has approved Bio-Rad’s iQ-Check Aspergillus Real-Time PCR Detection Kit for the detection of four hazardous Aspergillus species: A. flavus, A. fumigatus, A. niger, and A. terreus in cannabis flower and in both nonsolvent- and solvent-based cannabis concentrates.
The iQ-Check Aspergillus Real-Time PCR Detection Kit is validated by the AOAC Research Institute under its Performance Tested Method program. To obtain the validation, a study was performed that resulted in no significant difference between the iQ-Check Aspergillus method and the reference method. The kit was evaluated on parameters such as robustness, product consistency, stability, inclusivity and exclusivity, and matrix studies. In addition, Bio-Rad’s iQ-Check Free DNA Removal Solution was validated as part of the workflow for testing cannabis flower.
The fast and accurate test uses a simple workflow that includes gene amplification and real-time PCR detection. After enrichment and DNA extraction, the test harnesses the sensitivity and specificity of Bio-Rad’s PCR technology to perform real-time PCR. Next, Bio-Rad’s CFX Manager IDE Software automatically generates and analyzes the results.
Three other kits in Bio-Rad’s cannabis microbial testing product portfolio recently received AOAC approval for cannabis flower matrix: the iQ-Check Salmonella II, iQ-Check STEC VirX, and iQ-Check STEC SerO II PCR Detection Kits.
Please visit bio-rad.com/cannabis to learn more about the iQ-Check Aspergillus Real-Time Detection Kit and Bio-Rad’s complete range of iQ-Check real-time PCR test kits for cannabis microbial testing.
BIO-RAD is a trademark of Bio-Rad Laboratories, Inc. and IQ-CHECK is a trademark of Bio-Rad Europe GmbH in certain jurisdictions.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,100 employees worldwide. Bio-Rad had revenues exceeding $2.5 billion in 2020. For more information, please visit bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Press Contact:
Bio-Rad Laboratories, Inc.
Wendy Lauer
510-741-5653
wendy_lauer@bio-rad.com
CG Life
Ben Marcus
847-302-8430
bmarcus@cglife.com